GW Pharmaceuticals

GW is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, EPIDIOLEX (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury. The Company has additional cannabinoid product candidates in clinical trials for autism and schizophrenia.

Canopy Growth

Amplify Seymour Cannabis ETF

Amplify Alternative Harvest ETF

AdvisorShares Pure US Cannabis ETF

Global X Cannabis ETF

Trulieve Cannabis Corp.

AXS Cannabis ETF

Cambria Cannabis ETF

AdvisorShares Pure Cannabis ETF 

During a recessionary environment is historically when VCs make a ton of money.

Investing During A Recession (Podcast Transcript)

Aphria

Cronos Group

GrowGeneration Corp

Innovative Industrial Properties

CNBC's cannabis expert Tim Seymour discusses the recent developments in the space.

Should You Buy Cannabis Stocks & ETFs Now?

- Results from analysis of three P hase 3 clinical studies showed statistically significant improvement in spasticity in people with multiple sclerosis

Greenwich Biosciences to Present Analysis of Three Clinical Studies of Nabiximols for People with Multiple Sclerosis Related Spasticity at the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly

Company saw a surprise upside in revenues and earnings for the latest quarter. Strong pipeline means a continued revenue stream into the future.

GW Pharmaceuticals: Buy This Stock With Strong Guidance And A Solid Pipeline

LONDON and CARLSBAD, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Stifel Virtual Healthcare Conference on Wednesday, November 18, 2020 at 1:20 pm EST.

GW Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference

Teradyne

ArcBest

Gates Industrial

With the fourth quarter almost half over, and most of the third-quarter earnings reports long since posted, most on Wall Street are reasonably satisfied with the results.

Goldman Sachs Shifts Price Targets on 4 Red-Hot Stocks to Buy

GW Pharmaceuticals' latest earnings report reinforces the narrative that the company's future growth trajectory looks solid. Epidiolex still has a lot of growth potential in the short and long term, with a lot of market share remaining to be taken in different segments.

GW Pharmaceuticals Plc Remains A Solid Growth Story

GW Pharmaceuticals is an "underappreciated story," an analyst said as GWPH stock jumped higher on Wednesday for the second day running on better-than-expected third-quarter revenue. The post Cannabis Biotech Continues Two-Day Run On Unexpected Sales Beat appeared first on Investor's Business Daily.

Cannabis Biotech Continues Two-Day Run On Unexpected Sales Beat

GW Pharmaceuticals (GWPH) news for Wednesday includes GWPH stock continuing to rise after the release of its Q3 earnings report yesterday. The post GW Pharmaceuticals News: Why GWPH Stock Is Running 27% High Today appeared first on InvestorPlace.

GW Pharmaceuticals News: Why GWPH Stock Is Running 27% High Today

GW Pharmaceuticals plc's (GWPH) CEO Justin Gover on Q3 2020 Results - Earnings Call Transcript

Shares of GW Pharmaceuticals PLC jumped 18% Tuesday, after the biotech posted a narrower-than-expected third-quarter loss and a revenue beat and said a delayed late-stage trial of its cannabinoid-based treatment for multiple sclerosis spasticity can now proceed.

Cannabis Watch: GW Pharma shares rally on earnings and news of late-stage trial of cannabis-based treatment for MS patients

Momentum for Epidiolex remains very strong.

How GW Pharmaceuticals Blew Away Expectations With Its Q3 Results

The cannabinoid prescription drug Sativex has already been approved in numerous countries for reducing spasticity caused by MS.

GW Pharmaceuticals Initiates Phase 3 Trial for Multiple Sclerosis Drug

Shares of GW Pharmaceuticals PLC rallied 4.7% in premarket trading Tuesday, after the biopharmaceutical company developing therapeutics from its cannabinoid product platform reported a narrower-than-expected loss on revenue that rose above forecasts. The company also said it initiated a Phase 3 trial of a multiple sclerosis treatment.

GW Pharmaceuticals loss narrows more than expected and revenue beats; stock rallies

- Total revenue increased 51 percent to $ 137.1 million –  - Epidiolex for seizures associated with TSC launch ed in the U.S. - - Nabiximols Phase 3 program in MS spasticity now recruiting - - Conference call today at 8 :30 a .m. E S T -

GW Pharmaceuticals plc Reports Third Quarter 2020 Financial Results and Operational Progress

Shares of GW Pharmaceuticals PLC were indicated up more than 6% in premarket trading Tuesday, after the biopharmaceutical company developing therapeutics from its cannabinoid product platform said it initiated a Phase 3 trial of nabiximols, for multiple scelrosis-associated spasticity. The initiation of the trial had been delayed because of the COVID-19 pandemic.

GW Pharmaceuticals stock set to rally after Phase 3 trial of MS treatment to start, after COVID-19-related delay

CARLSBAD, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, today announced that the Company has initiated the first U.S. Phase 3 clinical trial studying nabiximols for multiple sclerosis (MS)-associated spasticity. Nabiximols, known as Sativex® outside of the U.S. and approved for use to treat MS spasticity in over 25 countries, is a complex botanical medicine formulated from extracts of the cannabis plant administered as an oral spray. Positive results from three previous European Phase 3 clinical studies show nabiximols was well-tolerated and provided continued reductions in patient-reported spasticity for individuals with MS.

GW Pharmaceuticals Initiates Pivotal Phase 3 Study of Nabiximols for Multiple Sclerosis-Associated Spasticity

Curaleaf Holdings, Inc.

Altria

Scotts Miracle-Gro

Constellation Brands

Investors keep waiting for marijuana stocks to come to life. In 2020, the Prime Alternative Harvest Index, which covers many of the major global cannabis companies, hasn't been good.

10 Best Marijuana Stocks to Buy for 2021

GW Pharmaceuticals (GWPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for GW Pharmaceuticals (GWPH)

Investors should study the various revenue streams for "epidiolex". Level of cash reserves important to judge likelihood of future share dilution.

GW Pharmaceuticals Q3 Earnings May Provide Clarity On Many Issues

LONDON and CARLSBAD, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on November 3rd, 2020 its financial results and operational progress for the third quarter ending September 30th, 2020. GW will also host a conference call the same day at 8:30 a.m. EST. Conference call information will be provided in the financial results press release and on the Company website (www.gwpharm.com) in the investor section. A replay of the call will also be available through the Company's website shortly after the call.

GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Third Quarter Ending September 30th, 2020 and Host Conference Call on November 3rd, 2020

-- Technology p rovide s a n ew w ay for the community to c ommunicate and c onnect -- -- Launching in collaboration with patient advocacy organizations, this web-based, i mage-recognition t echnology bridges music and art to provide a voice for those who struggle to express themselves --

Greenwich Biosciences, Inc., a Subsidiary of GW Pharmaceuticals plc, Launches unspoken symphony, a Breakthrough Innovation Created for the US Epilepsy Community

Marijuana stocks typically have high levels of risk for investors, but these three stocks deserve to be on your radar. The post 3 Marijuana Stocks to Buy With Decriminalization on the Table appeared first on InvestorPlace.

3 Marijuana Stocks to Buy With Decriminalization on the Table

Tilray Brands

Investing in marijuana is speculative, but, with these marijuana ETFs you can get in on the cannabis investing game and reduce risk. The post The 5 Best Marijuana ETFs for Conservative Portfolios appeared first on InvestorPlace.

The 5 Best Marijuana ETFs for Conservative Portfolios

Green Thumb Industries Inc.

The sector has seen its ups and downs, but some of the most promising stocks out there today are marijuana-related.

News for GW Pharmaceuticals Stock (GWPH)